Iwamiya, Metcela’s co-CEO, spoke at ACCJ x LINK-J event: “The Front Line of the Regenerative Medicine Business: Practical Application of Cell Medicine”
One of our Co-CEO, Iwamiya, spoke at an event hosted by The American Chamber of Commerce in Japan (ACCJ) and supported by the Life Science Innovation Network Japan (LINK-J).
|Title:||The Front Line of the Regenerative Medicine Business: Practical Application of Cell Medicine|
|Time:||December 10, 17:00-19:00 JST|
|About the event:||
In this fifth session of our Technology Series, the ACCJ-Kansai Business Programs Committee is pleased to welcome Dr. Takahiro Iwamiya, co-founder of Metcela Inc. The number of patients with heart failure is on the rise worldwide. Providing new treatment opportunities for this disease is an urgent issue, as there is concern that—due to the so-called heart failure pandemic—the number of cases and patients, as well as medical expenses, will increase.
Against this backdrop, Metcela is developing a combination regenerative medicine product: 1) VCAM1-positive cardiac fibroblasts (VCF) which assist with myocardial regeneration, and 2) a catheter for cell administration.In this session, Dr. Iwamiya will discuss: